Description
Anetumab Ravtansine is fully human IgG1 monoclonal antibody (anetumab) directed against the cell surface glycoprotein mesothelin and conjugated to the maytansinoid DM4 with potential antineoplastic activity. DM4 moiety binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of mesothelin-expressing tumor cells. Mesothelin is overexpressed on all mesotheliomas as well as many ovarian and pancreatic cancers while minimally expressed on normal tissue.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Anetumab Ravtansine are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Anetumab Ravtansine present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Anetumab Ravtansine antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Anetumab Ravtansine in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!